Your activity: 2 p.v.

COVID-19: Issues related to solid organ transplantation

COVID-19: Issues related to solid organ transplantation
Authors:
Ajit P Limaye, MD, FACP, FIDSA
Karen Hardinger, PharmD, BCPS
Section Editors:
Daniel C Brennan, MD, FACP
Emily A Blumberg, MD
Deputy Editors:
Albert Q Lam, MD
Sheila Bond, MD
Literature review current through: Nov 2022. | This topic last updated: Nov 08, 2022.

INTRODUCTION — Solid organ transplant recipients may be at increased risk for coronavirus disease 2019 (COVID-19) because they are immunosuppressed and are less likely to mount effective immune responses to vaccination.

This topic reviews aspects of COVID-19 that are specific to solid organ transplantation, including screening prior to transplantation, distinct clinical features, managing immunosuppression, and important drug interactions. Other aspects of COVID-19 care are discussed separately:

(See "COVID-19: Epidemiology, virology, and prevention".)

(See "COVID-19: Clinical features" and "COVID-19: Diagnosis".)

(See "COVID-19: Management in hospitalized adults".)

(See "COVID-19: Evaluation of adults with acute illness in the outpatient setting" and "COVID-19: Management of adults with acute illness in the outpatient setting".)

(See "COVID-19: Vaccines".)

(See "COVID-19: Infection prevention for persons with SARS-CoV-2 infection".)

In addition, please refer to our COVID-19 homepage to view the complete list of UpToDate COVID-19 topics.

RISK OF TRANSMISSION

Potential for donor-derived infection — Donor-derived severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been reported with lung transplantation but not with other organs [1]. For nonlung organ transplantation, data from case series have shown that transplantation of nonlung organs from SARS-CoV-2-infected donors can be safely performed [1-6]. While data is limited, there is no evidence that nonlung organ transplantation from a SARS-CoV-2-infected donor leads to worse short-term outcomes.

Bloodborne transmission has not been reported and is not expected; the frequency, duration, and magnitude of SARS-CoV-2 viremia are low [7-10]. (See "Blood donor screening: Medical history", section on 'Active or prior COVID-19'.)

Posttransplantation risk — It is not known whether solid organ transplant recipients are at higher risk for acquiring SARS-CoV-2 infection than the general population. However, chronic immunosuppression may lower the infectious dose needed to cause infection and impair adequate immune control once infection is established.

Like other immunosuppressed persons, solid organ transplant recipients may shed greater amounts of virus for longer durations than otherwise healthy hosts. Thus, they may be more likely to spread infection to others. Further data are needed to confirm these theories and to quantify viral dynamics and the risk of transmission to others.

DEFERRAL OF NONURGENT TRANSPLANTATION — To minimize the risk of infection and conserve hospital resources, elective transplantation (eg, living-donor kidney transplantation) and nonurgent, deceased-donor transplantation were deferred early in the pandemic at some transplant centers where the community prevalence of COVID-19 is high and/or where resources (personnel, hospital or intensive care unit [ICU] beds, operating rooms, other equipment) are limited [11-15].

The Centers for Medicare & Medicaid Services have classified organ transplantation as a tier 3b activity: Do not delay, on the basis of assessment of the potential risks compared with known benefits [16]. The risk-benefit ratio for delaying elective transplantation during the pandemic is not clear. Limited data suggest that patients who are waitlisted for kidney transplantation had a higher risk of hospitalization and death compared with patients who were transplanted [17]. Modelling data provide further support for kidney transplantation during the pandemic, at least for select populations [18].

PRETRANSPLANTATION SCREENING — All organ donors and potential recipients should be screened for COVID-19 prior to organ procurement. This is to reduce the risk for progression to severe COVID-19 with potent immunosuppression and to initiate appropriate infection prevention measures (eg, airborne precautions) for the safety of the organ procurement team.

Reverse-transcriptase polymerase chain reaction (RT-PCR; primarily used to detect active infection) is the main assay used for screening. (See "COVID-19: Diagnosis", section on 'Choosing an initial diagnostic test'.)

Donor screening — All donors should be screened for SARS-CoV-2 infection [19]. We generally perform a careful history, obtain chest imaging, and perform microbiologic testing. In all cases the decision to proceed to transplantation should consider the urgency of the transplant and the risk and benefits in each individual. General principles adapted from the American Society of Transplantation (AST) guidelines and Organ Procurement and Transplantation Network (OPTN) on SARS-CoV-2 donor evaluation and testing are below [20,21]:

Living donors

Self-quarantine for 14 days prior to donation should be considered to reduce the risk of SARS-CoV-2 infection. At a minimum, we ask donors to avoid high risk activities and to mask and take other general precautions prior to donation.

At the time of donation, donors should be screening for symptoms and potential exposures. Chest imaging and nucleic acid amplification testing (NAAT) for SARS-CoV-2 from a respiratory tract sample should be performed within 72 hours of donation (but ideally as close as possible to the time of donation).

Deceased donors

Screening should include assessing for past COVID-19, recent exposures, and the timing of these events relative to the donation.

NAAT for SARS-CoV-2 should be performed on nasopharyngeal samples from deceased donors within 72 hours and, ideally, as close as possible to organ recovery. When lungs are recovered for transplantation, NAAT for SARS-CoV-2 should be performed on both nasopharyngeal and lower respiratory tract samples.

Lung transplantation from donors with active infection is generally avoided. Some centers have avoided the use of donors with active infection and death due to severe COVID-19 or donors with thrombotic complications due to COVID-19.

For donors with resolved COVID-19 who test positive by NAAT, the decision to proceed to transplantation should be on a case-by-case basis and take into account the urgency of transplantation and the risk of recipient mortality if transmission occurs. In general, for donors who recovered from COVID-19 21 to 90 days prior to donation, the likelihood of transmission via transplantation of nonlung organs is low and a positive NAAT is not thought to reflect active/transmissible virus. For those who more recently recovered or who have no clear history of COVID-19, the risk for transmission is not fully known but appears to be low. There are increasing reports of transplantation of nonlung organs from donors with recent SARS-CoV-2 infection that do not lead to viral transmission and have good short-term patient and graft outcomes. Long-term outcomes are not well characterized.

Similarly, for donors who have been exposed but test negative, the safety of donation is not known. In all cases, consultation with an infectious disease expert can help with test interpretation and risk-benefit analysis [20]. The OPTN has provided a summary of the evidence to help guide decision-making.

Candidate screening — All potential organ transplant recipients should be screened for COVID-19 by history, chest imaging, and microbiologic testing prior to transplantation. Although data are lacking, COVID-19 can be asymptomatic, and there is concern that the intensive immunosuppression given at the time of transplantation could result in rapidly progressive and potentially fatal COVID-19:

All potential organ recipients should be screened for COVID-19 prior to transplantation. At most transplant centers this includes NAAT of an upper respiratory tract specimen (eg, nasopharyngeal swab), a thorough symptom and exposure history, and chest imaging. A chest radiograph is usually sufficient for patients who lack respiratory symptoms, however, for those with respiratory symptoms (even if minor), computed tomography (CT) of the chest is appropriate.

Candidates with active COVID-19 should generally be deferred for transplantation.

For patients with active COVID-19 and patients who screen positive, the optimal deferral period is not known. The AST suggests waiting until all symptoms have resolved and at least one NAAT for SARS-CoV-2 has been negative [19,22]. Some centers prefer to have two negative NAATs for enhanced sensitivity. However, as with any transplantation, the risk of transplantation must be balanced with the risk of not transplanting a patient with acute or recent COVID-19.

PREVENTION

General measures — Preventive measures for organ transplant recipients are similar to those defined for the general population. However, we continue to advise vaccinated transplant recipients to maintain personal measures to minimize exposure to SARS-CoV-2 (eg, masking, distancing, avoiding crowds when possible) because early data suggest that vaccine response is suboptimal and that newer omicron variants are more readily transmitted, regardless of vaccination status. (See "COVID-19: Epidemiology, virology, and prevention", section on 'Prevention'.)

One additional consideration is that solid organ transplant recipients who have COVID-19 may shed greater amounts of virus for longer durations than nonimmunosuppressed patients [23,24]. Thus, a longer duration of isolation and/or testing may be needed to document viral clearance to help reduce the likelihood of spreading the infection to others [25]. (See "COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Infection prevention in the home setting' and "COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'.)

Centers for Disease Control and Prevention (CDC) guidance on the duration of isolation and quarantine for immunocompromised patients can be found here.

Vaccination — All transplant recipients are eligible for vaccination, unless contraindicated (eg, hypersensitivity to the vaccine or its components). Although the immunogenicity and efficacy of COVID-19 vaccines are lower in solid organ transplant recipients than the general population [26,27], the benefit from vaccination outweighs risk. Solid organ transplant recipients should continue to adhere to protective measures (such as masking and social distancing) despite vaccination, based upon data suggesting a suboptimal immune response among transplant recipients [28-32] and studies suggesting lower efficacy against severe disease [33,34].

Timing – The ideal timing of vaccination in the posttransplantation setting is not known. In all cases, we weigh the likelihood of contracting COVID-19 (based on community prevalence) against the probability of developing a protective immune response to vaccination.

Whenever possible, vaccination should occur prior to transplantation (ideally with completion of a vaccine series a minimum of two weeks prior to transplant).

If vaccination prior to transplantation is not possible, we delay vaccination for at least one month from the time of transplantation and for at least three months after use of T cell-depleting agents (eg, anti-thymocyte globulin) or specific B cell-depletion agents (eg, rituximab) [35].

For patients who are transplanted between vaccine doses, we delay the second dose until at least one month after transplantation (if induction did not include a T or B cell-depleting agent) and for three months when a T or B cell-depleting agent was used for induction.

These recommendations are consistent with expert guidance from International Society for Heart and Lung Transplantation (ISHLT) [35]; the American Society of Transplantation (AST) also recommends vaccinating at least two weeks before transplantation but does not specify whether vaccination should be delayed when T or B cell-depleting agents are used [36].

Dose and interval – The humoral immune response to COVID-19 vaccination is impaired in solid organ transplant recipients [28-30,32]. Several studies have found that the antibody response to a two-dose mRNA vaccine is substantially lower in solid organ transplant recipients when compared with the general population [28,29,32,37]. Poor immune response was associated with the use of antimetabolite immunosuppression in one study [29]. However, observational studies assessing the "real-world" impact of vaccination among transplant recipients have shown that receipt of mRNA vaccine is associated with a lower risk of SARS-CoV-2 infection, although these studies predated the emergence of the Omicron variant [38-42].

Administering a third dose to solid organ transplant recipients is associated with improved immunogenicity in a significant number of individuals and appears to be safe. The US Food and Drug Administration (FDA) approved third doses of mRNA COVID-19 vaccine for many immunosuppressed patients, including solid organ transplant recipients, based upon multiple studies showing improved immune response [43-48]. While additional vaccine doses may improve immune response [49-53], they appear to have reduced effectiveness at neutralizing the Omicron variant compared with wild-type SARS-CoV-2 or other variants [54,55]. Guidance from the Advisory Committee on Immunization Practices recommended administration of the same mRNA vaccine used in the primary series whenever possible; the vaccine should be given a minimum of 28 days after the second dose. (See "COVID-19: Vaccines", section on 'Immunocompromised individuals'.)

Response to vaccination among solid organ transplant recipients may be determined by measuring antibody responses, cellular immune responses (not commercially available), and overall effectiveness. While antibody responses are diminished compared with those in healthy controls [56], T cell responses may be present in the absence of humoral immunity (and vice versa) [57-60], and although breakthrough infections occur in fully vaccinated solid organ transplant recipients, the severity of illness appears to be diminished.

Booster doses – Because of the possibility of waning immunity and decreased efficacy against more virulent variants, the FDA and the Centers for Disease Control and Prevention (CDC) have approved two booster doses for all adults 18 years or older, regardless of the vaccine received.

Booster doses in the general population are a distinct issue from administering a third dose of an mRNA vaccine for the primary series in solid organ transplant recipients. Solid organ transplant recipients who received three doses of a primary mRNA vaccine series may also receive a booster dose six months later. However, there are no available data on the efficacy of booster doses in solid organ transplant recipients.

Further details on the indications and approach to booster vaccinations are discussed separately. (See "COVID-19: Vaccines", section on 'Role of booster vaccinations'.)

Immunosuppression and vaccine response – The optimal approach to managing immunosuppression around the time of vaccination is not known, and approaches vary among experts:

For transplant recipients outside of the early posttransplantation period, there are insufficient data to guide modifications of immunosuppression in anticipation of, or preparation for, vaccination, and society guidelines do not recommend routine modification of immunosuppression [61]. However, some experts favor holding the antimetabolite around the time of vaccination to maximize the likelihood of developing protective immunity [62]; there is no specific evidence to guide how best to adjust immunosuppression with respect to timing, duration, or specific medication adjustment. One retrospective study of kidney transplant recipients found an association between mammalian (mechanistic) target of rapamycin (mTOR) inhibitor therapy and improved humoral and cellular immune response to a two-dose mRNA vaccine [63]; however, additional studies are needed to confirm these findings. A clinical trial evaluating the effects of immunosuppression reduction on vaccine response is in progress (NCT05060991).

For those receiving B or T cell-depleting therapy for rejection or other indications, we may delay vaccination for one to three months depending on the agent used.

Available studies have not reported an increased rate of acute allograft rejection with vaccination, but longer-term follow-up and assessment of donor-specific antibodies are needed.

Specific details on vaccine administration (eg, intervals between vaccination, lack of need for serologic testing) are similar to those for the general population. (See "COVID-19: Vaccines".)

Breakthrough infections after vaccination – Breakthrough infections among vaccinated solid organ transplant patients, including cases requiring hospitalization and mechanical ventilation, have been reported [64-70]. Although the overall incidence of breakthrough infections among vaccinated transplant patients is low, it appears to be greater than that among vaccinated individuals in the general population. (See "COVID-19: Vaccines", section on 'Breakthrough infections after vaccination'.)

Preexposure prophylaxis — Preexposure prophylaxis (PrEP) with tixagevimab plus cilgavimab is appropriate for solid organ transplant patients (aged ≥12 years) who are receiving immunosuppressive treatment [71] (see 'Vaccination' above). Although potential cardiac adverse events have been reported with tixagevimab plus cilgavimab, its use is not contraindicated in heart transplant recipients. Details on administration are discussed separately. (See "COVID-19: Epidemiology, virology, and prevention", section on 'Pre-exposure prophylaxis for selected individuals'.)

Food and Drug Administration (FDA) guidance on emergency use authorization can be found here.

Postexposure prophylaxis — Solid organ transplant recipients who have had close contact with an individual with SARS-CoV-2 infection or who are at high risk of exposure to individuals with infection in an institutional setting are eligible for prophylactic monoclonal antibody treatment because of their immunosuppressed state. However, the efficacy of monoclonal antibody treatment varies among SARS-CoV-2 variants, and administration may not be appropriate, depending upon the predominant variant in circulation. (See "COVID-19: Epidemiology, virology, and prevention", section on 'Limited role for post-exposure prophylaxis'.)

ACTIVE COVID-19 IN SOLID ORGAN TRANSPLANT RECIPIENTS

Clinical presentation

Clinical features — Clinical features of COVID-19 among solid organ transplant recipients are variable and similar to those in immunocompetent patients. However, fever appears to be less common, possibly as a consequence of the effects of immunosuppressive therapy on the systemic inflammatory response [72-76]. As an example, in two case series of solid organ transplant recipients in New York City, fever was a presenting symptom in only 58 to 70 percent [73,74]. Lymphopenia is also common and may be more profound than in nontransplant patients with COVID-19 [74,76].

Severity of illness — The incidence of COVID-19 infection is similar or slightly higher among solid organ transplant recipients compared with the general population. Hospitalization rates are also higher among solid organ transplant recipients [77]. However, among those who require hospitalization, the risk for mortality appears to be similar to that for the general population when adjusted for comorbidities [77-83]. Severity of disease among solid organ transplant recipients appears to be attenuated with the Omicron variant compared with prior variants [84].

Risk factors for severe COVID-19 are discussed in detail elsewhere. (See "COVID-19: Clinical features", section on 'Risk factors for severe illness'.)

Effect of immunosuppression — The impact of immunosuppression in the solid organ transplant population on COVID-19 disease severity remains unclear. The pathogenesis of COVID-19 appears to represent an interplay between direct virally mediated injury and the associated host response, with experimental data suggesting that a dysregulated and hyperintense immune response may mediate more severe disease [85]. Since immunosuppressive agents modulate several aspects of the host immune response, the severity of COVID-19 could potentially be affected by the type, combinations, and intensity of immunosuppression. As an example, certain immunosuppressive medications can either directly (eg, lymphocyte-depleting antibodies) or indirectly (eg, antimetabolites) cause lymphopenia, which is a reported risk factor for severe COVID-19 illness [86,87]. Specific agents that have been independently associated with decreased immune responses to vaccines (eg, mammalian [mechanistic] target of rapamycin [mTOR] inhibitors, mycophenolate) could theoretically impair the ability to develop an adequate immune response to natural infection. Conversely, some experimental data suggest that mTOR inhibitors may have some biological activity against SARS-CoV-2 [88]. Additional studies are required to determine the impact of specific immunosuppressive agents on the course of COVID-19.

Diagnosis — Criteria for testing for COVID-19 in solid organ transplant recipients are similar to those for the general population. However, clinicians should have a higher index of suspicion of infection, as is generally recommended for immunosuppressed individuals (table 1):

For solid organ transplant recipients with suspected COVID-19 who are hospitalized, testing is recommended.

For solid organ transplant recipients with mild symptoms, optimal practice is not defined. While some favor testing all such patients based upon the potential for rapid disease progression and early treatment, others favor making a clinical diagnosis and monitoring the patient at home. Thus, the decision is often individualized based upon local COVID-19 prevalence, available resources, and patient-provider preference. (See "COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Therapies of limited or uncertain benefit'.)

Routine screening of asymptomatic solid organ transplant recipients is not recommended.

Specific testing and screening methods are discussed separately. (See "COVID-19: Diagnosis", section on 'Clinical suspicion' and "COVID-19: Infection prevention for persons with SARS-CoV-2 infection".)

Management

General considerations — The approach to the management of acute COVID-19 in solid organ transplant recipients is similar to that for nontransplant patients; however, because of their immunosuppressed status, the threshold to treat early and mild infections and provide post- or preexposure prophylaxis is lower (algorithm 1). In addition, careful attention should be paid to drug-drug interactions. (See 'Drug-drug interactions' below.)

These issues are discussed in more detail separately:

(See "COVID-19: Management of adults with acute illness in the outpatient setting".)

(See "COVID-19: Management in hospitalized adults".)

(See "COVID-19: Clinical manifestations and diagnosis in children".)

(See "COVID-19: Management of the intubated adult".)

Adjusting immunosuppression — Adjustments to the immunosuppressive regimen are necessarily individualized, based upon disease severity, the specific regimen used, type of organ transplanted, time posttransplant, and the risk of acute allograft rejection [73,76,78,86,87,89-91].

Although the optimal approach is not defined, we usually reduce immunosuppression in patients with moderate to severe COVID-19 (eg, those requiring hospitalization):

As a first step, we often reduce or hold the antimetabolite (eg, mycophenolate mofetil/sodium), particularly for patients with lymphopenia (eg, absolute lymphocyte count <700 cells/mL).

We generally continue the calcineurin inhibitor (CNI) because CNIs inhibit interleukin (IL) 6 and IL-1 pathways; these cytokines may contribute to the development of the severe, dysregulated immune response seen in some patients with severe COVID-19.

In all cases the decision to reduce immunosuppression must be carefully weighed against the risk for acute rejection, particularly in transplant recipients who generally require high levels of maintenance immunosuppression (eg, lung or heart recipients). Data supporting our approach and any other are limited to observational studies [73,74,76,78,92,93]. In addition, this approach does not preclude the use of high-dose glucocorticoids and other immunomodulators for severe COVID-19 infection.

There are also concerns that COVID-19 itself may increase the risk for acute rejection and that an overly intense inflammatory host immune response might contribute to overall disease severity. Thus, attenuating the immune response by maintaining low-dose immunosuppression could theoretically be beneficial. In addition, experimental data suggest that certain immunosuppressive agents such as mTOR inhibitors may have some biological activity against SARS-CoV-2 [88]. Additional studies are required to confirm these findings.

Additional guidance on adjusting immunosuppression in transplant recipients with active infection can be found in the following topic reviews:

(See "Kidney transplantation in adults: Maintenance immunosuppressive therapy", section on 'Patients who develop an infection'.)

(See "Maintenance immunosuppression following lung transplantation", section on 'Monitoring and adjusting maintenance therapy'.)

(See "COVID-19: Evaluation and management of cardiac disease in adults", section on 'Cardiac transplantation'.)

Recommendations from specific medical societies are listed separately. (See 'Society guideline links' below.)

Drug-drug interactions — Several new antiviral medications are being evaluated or have already been approved for treatment of COVID-19 (see "COVID-19: Management in hospitalized adults", section on 'Specific treatments'). Clinicians should be aware that these medications have potential drug-drug interactions with immunosuppressive medications that are commonly used among solid organ transplant recipients (such as CNIs) (table 2). If these immunosuppressive agents are continued during COVID-19 infection, their blood levels should be frequently monitored [94].

As an example, nirmatrelvir-ritonavir has been authorized for emergency use by the United States Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in adults and children at high risk for progression to severe disease. Nirmatrelvir-ritonavir is an inhibitor of CYP3A and may increase plasma concentrations of drugs that are primarily metabolized by CYP3A. Concomitant use with sirolimus should be avoided, and blood levels of other immunosuppressive agents (such as CNIs) should be monitored. (See "COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Nirmatrelvir-ritonavir as preferred therapy' and "COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Therapies of limited or uncertain benefit'.)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: COVID-19 – Index of guideline topics".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topics (see "Patient education: COVID-19 overview (The Basics)" and "Patient education: COVID-19 vaccines (The Basics)")

SUMMARY AND RECOMMENDATIONS

Challenges for organ transplantation – COVID-19 poses challenges for individual solid organ transplant candidates and recipients and the process of organ transplantation. (See 'Introduction' above.)

Risk of transmission – Donor-derived SARS-CoV-2 infection has been reported through lung transplantation but not via nonlung transplantation. (See 'Potential for donor-derived infection' above.)

Screening before transplantation – Because of the risk for progression to severe disease and the potential for transmitting SARS-CoV-2 to health care providers, all solid organ donor and transplant candidates should be screened for COVID-19 by history, chest imaging, and microbiologic testing. (See 'Pretransplantation screening' above.)

Posttransplant risk – Posttransplantation, solid organ transplant recipients may be at increased risk for acquisition of infection, progression to symptomatic infection, and/or development of more severe COVID-19. (See 'Posttransplantation risk' above.)

Clinical manifestations – The clinical manifestations of COVID-19 in solid organ transplant recipients are variable and generally similar to those observed in nonimmunocompromised patients. However, fever appears to be less common. (See 'Clinical presentation' above and 'Severity of illness' above.)

Diagnosis – The approach to diagnosis is similar to that for the general population. Because signs and symptoms of COVID-19 may be subtle in transplant recipients and disease progression can be rapid, some clinicians have a lower threshold for evaluating and testing transplant recipients. (See 'Diagnosis' above.)

Management approach – The approach to management (eg, use of antivirals, supportive care) is also similar to that for the general population, although the threshold for monoclonal antibody use is lower. Careful attention should be paid to potential drug-drug interactions and effects on the immunosuppressive regimen. (See 'General considerations' above and 'Drug-drug interactions' above.)

Adjusting immunosuppression – Adjustments to the immunosuppressive regimen are necessarily individualized, based upon disease severity, the specific regimen used, type of organ transplant, time posttransplant, and the risk of acute allograft rejection. Some organ transplant recipients recover without reduction in immunosuppression, which carries the risk of rejection and immune reconstitution. Conversely, continued immunosuppression may enhance the risk of uncontrolled infection. (See 'Adjusting immunosuppression' above.)

Vaccination – All transplant recipients are eligible for vaccination with an extended dose vaccine series, unless contraindicated (eg, hypersensitivity to the vaccine or its components). The ideal timing in the posttransplantation setting is uncertain. Because early data suggest that vaccine response is suboptimal, we continue to advise that vaccinated transplant recipients maintain personal measures to minimize exposure to SARS-CoV-2 (eg, masking, distancing, avoiding crowds when possible). (See 'Vaccination' above and 'General measures' above.)

Preexposure prophylaxis – Preexposure prophylaxis (PrEP) with tixagevimab plus cilgavimab is appropriate for solid organ transplant patients (aged ≥12 years) who are receiving immunosuppressive treatment and may not have an adequate immune response to vaccination. (See 'Preexposure prophylaxis' above.)

  1. Kute VB, Fleetwood VA, Meshram HS, et al. Use of Organs from SARS-CoV-2 Infected Donors: Is It Safe? A Contemporary Review. Curr Transplant Rep 2021; 8:281.
  2. Koval CE, Poggio ED, Lin YC, et al. Early success transplanting kidneys from donors with new SARS-CoV-2 RNA positivity: A report of 10 cases. Am J Transplant 2021; 21:3743.
  3. Neidlinger NA, Smith JA, D'Alessandro AM, et al. Organ recovery from deceased donors with prior COVID-19: A case series. Transpl Infect Dis 2021; 23:e13503.
  4. Bock MJ, Vaughn GR, Chau P, et al. Organ transplantation using COVID-19-positive deceased donors. Am J Transplant 2022; 22:2203.
  5. Schold JD, Koval CE, Wee A, et al. Utilization and outcomes of deceased donor SARS-CoV-2-positive organs for solid organ transplantation in the United States. Am J Transplant 2022; 22:2217.
  6. Dhand A, Okumura K, Nabors C, Nishida S. Solid organ transplantation from COVID positive donors in the United States: Analysis of United Network for Organ Sharing database. Transpl Infect Dis 2022; :e13925.
  7. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020; 323:1843.
  8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497.
  9. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfus Med Rev 2020; 34:75.
  10. Organ retrieval for transplantation in the COVID-19 era. American Society of Transplant Surgeons. https://asts.org/advocacy/covid-19-resources/asts-covid-19-strike-force/asts-covid-19-strike-force-organ-retrieval-guidance#.Xqb1BGhKiUl (Accessed on April 26, 2020).
  11. Loupy A, Aubert O, Reese PP, et al. Organ procurement and transplantation during the COVID-19 pandemic. Lancet 2020; 395:e95.
  12. Lentine KL, Vest LS, Schnitzler MA, et al. Survey of US Living Kidney Donation and Transplantation Practices in the COVID-19 Era. Kidney Int Rep 2020; 5:1894.
  13. Ahn C, Amer H, Anglicheau D, et al. Global Transplantation COVID Report March 2020. Transplantation 2020; 104:1974.
  14. Ahmed O, Brockmeier D, Lee K, et al. Organ donation during the COVID-19 pandemic. Am J Transplant 2020; 20:3081.
  15. Boyarsky BJ, Werbel WA, Durand CM, et al. Early national and center-level changes to kidney transplantation in the United States during the COVID-19 epidemic. Am J Transplant 2020; 20:3131.
  16. Non-emergent, elective medical services, and treatment recommendations. Centers for Medicare & Medicaid Services. https://www.cms.gov/files/document/cms-non-emergent-elective-medical-recommendations.pdf (Accessed on April 26, 2020).
  17. Craig-Schapiro R, Salinas T, Lubetzky M, et al. COVID-19 outcomes in patients waitlisted for kidney transplantation and kidney transplant recipients. Am J Transplant 2021; 21:1576.
  18. Massie AB, Boyarsky BJ, Werbel WA, et al. Identifying scenarios of benefit or harm from kidney transplantation during the COVID-19 pandemic: A stochastic simulation and machine learning study. Am J Transplant 2020; 20:2997.
  19. American Society for Transplantation. Information for transplant professionals and community members regarding 2019 novel coronavirus. https://www.myast.org/sites/default/files/1COVID19%20FAQ%20Tx%20Centers%2004.15.2020.pdf (Accessed on April 18, 2020).
  20. https://optn.transplant.hrsa.gov/media/kkhnlwah/sars-cov-2-summary-of-evidence.pdf (Accessed on December 03, 2021).
  21. https://optn.transplant.hrsa.gov/media/4576/policy_notice_lunglowerrespiratorytesting_20210426.pdf (Accessed on December 03, 2021).
  22. COVID-19: FAQs for Organ Transplantation. American Society of Transplantation. Updated January 29, 2022. (Available at: https://www.myast.org/sites/default/files/2022_Jan_29.%20Clean_FAQ_COVIDUpdates.pdf).
  23. Man Z, Jing Z, Huibo S, et al. Viral shedding prolongation in a kidney transplant patient with COVID-19 pneumonia. Am J Transplant 2020; 20:2626.
  24. Zhu L, Gong N, Liu B, et al. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China. Eur Urol 2020; 77:748.
  25. https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html (Accessed on January 21, 2022).
  26. Li J, Ayada I, Wang Y, et al. Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysis. Transplantation 2022; 106:2068.
  27. Phadke VK, Scanlon N, Jordan SC, Rouphael NG. Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients. Curr Transplant Rep 2021; 8:127.
  28. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA 2021; 325:1784.
  29. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA 2021; 325:2204.
  30. Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant 2021; 21:2719.
  31. https://www.myast.org/statement-covid-19-vaccination-solid-organ-transplant-recipients (Accessed on May 25, 2021).
  32. Shostak Y, Shafran N, Heching M, et al. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. Lancet Respir Med 2021; 9:e52.
  33. Heeger PS, Larsen CP, Segev DL. Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients. Sci Immunol 2021; 6.
  34. Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1553.
  35. SARS-CoV-2 Vaccination in Heart and Lung Transplantation: Recommendations from the ISHLT COVID-19 Task Force https://ishlt.org/ishlt/media/Documents/COVID19_Vaccine-Recommendations_3-15-2021.pdf (Accessed on March 19, 2021).
  36. American Society of Transplantation COVID-19 Vaccination Guidance . http://www.myast.org/sites/default/files/AST-COVID-PtVaccine-3.18.21-final.pdf (Accessed on March 21, 2021).
  37. Marion O, Del Bello A, Abravanel F, et al. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. Ann Intern Med 2021; 174:1336.
  38. Zahradka I, Petr V, Modos I, et al. Association Between SARS-CoV-2 Messenger RNA Vaccines and Lower Infection Rates in Kidney Transplant Recipients : A Registry-Based Report. Ann Intern Med 2022; 175:961.
  39. McEvoy CM, Lee A, Misra PS, et al. Real-world Impact of 2-dose SARS-CoV-2 Vaccination in Kidney Transplant Recipients. Transplantation 2022; 106:e279.
  40. Tucker M, Azar MM, Cohen E, et al. Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis. Transpl Infect Dis 2022; 24:e13876.
  41. Aslam S, Liu J, Sigler R, et al. Coronavirus disease 2019 vaccination is protective of clinical disease in solid organ transplant recipients. Transpl Infect Dis 2022; 24:e13788.
  42. Overvad M, Koch A, Jespersen B, et al. Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation-A Danish nationwide cohort study. Am J Transplant 2022; 22:2627.
  43. Kamar N, Abravanel F, Marion O, et al. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med 2021; 385:661.
  44. Werbel WA, Boyarsky BJ, Ou MT, et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann Intern Med 2021; 174:1330.
  45. Hall VG, Ferreira VH, Ku T, et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med 2021; 385:1244.
  46. Stumpf J, Tonnus W, Paliege A, et al. Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant. Transplantation 2021; 105:e267.
  47. Benotmane I, Gautier G, Perrin P, et al. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. JAMA 2021.
  48. Masset C, Kerleau C, Garandeau C, et al. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response. Kidney Int 2021; 100:1132.
  49. Alejo JL, Mitchell J, Chiang TP, et al. Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Transplantation 2021; 105:e280.
  50. Kamar N, Abravanel F, Marion O, et al. Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant. JAMA Netw Open 2021; 4:e2136030.
  51. Caillard S, Thaunat O, Benotmane I, et al. Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series. Ann Intern Med 2022; 175:455.
  52. Abedon AT, Teles MS, Alejo JL, et al. Improved Antibody Response After a Fifth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Transplantation 2022; 106:e262.
  53. Mitchell J, Alejo JL, Chiang TPY, et al. Antibody Response to a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: An Update. Transplantation 2022; 106:e338.
  54. Benning L, Morath C, Bartenschlager M, et al. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. Am J Transplant 2022; 22:1873.
  55. Karaba AH, Johnston TS, Aytenfisu TY, et al. A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. Transplantation 2022; 106:1440.
  56. Kamar N, Abravanel F, Marion O, et al. Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients. Am J Transplant 2022; 22:1467.
  57. Cucchiari D, Egri N, Bodro M, et al. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant 2021; 21:2727.
  58. Hall VG, Ferreira VH, Ierullo M, et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. Am J Transplant 2021; 21:3980.
  59. Rozen-Zvi B, Yahav D, Agur T, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect 2021; 27:1173.e1.
  60. Herrera S, Colmenero J, Pascal M, et al. Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients. Am J Transplant 2021; 21:3971.
  61. https://www.myast.org/sites/default/files/2021%2005%2018%20COVID19%20VACCINE%20FAQS-final%20update.pdf (Accessed on July 01, 2021).
  62. Kantauskaite M, Müller L, Kolb T, et al. Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients. Am J Transplant 2022; 22:634.
  63. Netti GS, Infante B, Troise D, et al. mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients. Am J Transplant 2022; 22:1475.
  64. Tsapepas D, Paget K, Mohan S, et al. Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients. Am J Kidney Dis 2021; 78:314.
  65. Malinis M, Cohen E, Azar MM. Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients. Am J Transplant 2021; 21:2916.
  66. Anjan S, Natori Y, Fernandez Betances AA, et al. Breakthrough COVID-19 Infections After mRNA Vaccination in Solid Organ Transplant Recipients in Miami, Florida. Transplantation 2021; 105:e139.
  67. Qin CX, Moore LW, Anjan S, et al. Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. Transplantation 2021; 105:e265.
  68. Aslam S, Adler E, Mekeel K, Little SJ. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transpl Infect Dis 2021; 23:e13705.
  69. Mehta RB, Silveira FP. COVID-19 after two doses of mRNA vaccines in kidney transplant recipients. Am J Transplant 2021; 21:4102.
  70. https://www.cdc.gov/mmwr/volumes/70/wr/mr7044e3.htm (Accessed on January 21, 2022).
  71. NIH. COVID-19 Treatment Guidelines. The COVID-19 Treatment Guidelines Panel's Statement on Tixagevimab Plus Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis for SARS-CoV-2 Infection. https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-evusheld-for-prep/ (Accessed on January 20, 2022).
  72. Guillen E, Pineiro GJ, Revuelta I, et al. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? Am J Transplant 2020; 20:1875.
  73. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant 2020; 20:1800.
  74. Akalin E, Azzi Y, Bartash R, et al. Covid-19 and Kidney Transplantation. N Engl J Med 2020; 382:2475.
  75. Tschopp J, L'Huillier AG, Mombelli M, et al. First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. Am J Transplant 2020; 20:2876.
  76. Caillard S, Anglicheau D, Matignon M, et al. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney Int 2020; 98:1549.
  77. Hadi YB, Naqvi SFZ, Kupec JT, et al. Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network. Transplantation 2021; 105:1365.
  78. Kates OS, Haydel BM, Florman SS, et al. Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. Clin Infect Dis 2021; 73:e4090.
  79. Bossini N, Alberici F, Delbarba E, et al. Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience. Am J Transplant 2020; 20:3019.
  80. Favà A, Cucchiari D, Montero N, et al. Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study. Am J Transplant 2020; 20:3030.
  81. Molnar MZ, Bhalla A, Azhar A, et al. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. Am J Transplant 2020; 20:3061.
  82. Avery RK. COVID-19 Therapeutics for Solid Organ Transplant Recipients; 6 Months Into the Pandemic: Where Are We Now? Transplantation 2021; 105:56.
  83. Avery RK, Chiang TP, Marr KA, et al. Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: A retrospective cohort. Am J Transplant 2021; 21:2498.
  84. Cochran W, Shah P, Barker L, et al. COVID-19 Clinical Outcomes in Solid Organ Transplant Recipients During the Omicron Surge. Transplantation 2022; 106:e346.
  85. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130:2620.
  86. Requião-Moura LR, Modelli de Andrade LG, de Sandes-Freitas TV, et al. The Mycophenolate-based Immunosuppressive Regimen Is Associated With Increased Mortality in Kidney Transplant Patients With COVID-19. Transplantation 2022; 106:e441.
  87. Gérard AO, Barbosa S, Anglicheau D, et al. Association Between Maintenance Immunosuppressive Regimens and COVID-19 Mortality in Kidney Transplant Recipients. Transplantation 2022; 106:2063.
  88. Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020; 34:327.
  89. Latif F, Farr MA, Clerkin KJ, et al. Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019. JAMA Cardiol 2020; 5:1165.
  90. Yi SG, Rogers AW, Saharia A, et al. Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center. Transplantation 2020; 104:2208.
  91. Nair V, Jandovitz N, Hirsch JS, et al. COVID-19 in kidney transplant recipients. Am J Transplant 2020; 20:1819.
  92. Zhong Z, Zhang Q, Xia H, et al. Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients. Am J Transplant 2020; 20:1916.
  93. Banerjee D, Popoola J, Shah S, et al. COVID-19 infection in kidney transplant recipients. Kidney Int 2020; 97:1076.
  94. Elens L, Langman LJ, Hesselink DA, et al. Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. Ther Drug Monit 2020; 42:360.
Topic 127582 Version 39.0

References